US-based clinical-stage oncology company TransCode Therapeutics, Inc. (NASDAQ: RNAZ) said it has entered into a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.
Polynoma's lead asset is seviprotimut-L, a Phase 3-ready polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma.
Concurrent with the acquisition, TransCode announced a USD25m equity investment from CK Life Sciences Int'l., (Holdings) Inc (HKG: 0775). The funding will primarily support advancement of TransCode's lead microRNA candidate, TTX-MC138, into a Phase 2 clinical trial.
Under the terms, Polynoma's sole stockholder, an indirect subsidiary of CK Life Sciences, will receive common and preferred shares in TransCode. CK Life Sciences will hold approximately 91% of the combined company on a fully diluted basis, valuing the business at about USD165m. Additional milestone payments of up to USD95m may be payable for seviprotimut-L.
TransCode expects to retain several professionals from Polynoma and will continue to develop both seviprotimut-L and TTX-MC138, alongside its pre-clinical RNA-based programs.
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio